The most common form of leishmaniasis that is transmitted through the bite of female phlebotomine sand flies or after exposure to leishmania parasites. It is characterized by skin lesions at the site ...
Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation for mucocutaneous leishmaniasis is limited due to its relatively low prevalence and the challenges associated with conducting systematic clinical studies. As a condition that affects fewer individuals, comprehensive data collection and characterization have not been prioritized. This can lead to feelings of uncertainty, but ongoing research aims to improve understanding and treatment options.
To navigate your care for mucocutaneous leishmaniasis, consider seeking out an infectious disease specialist with experience in tropical diseases. Additionally, you may want to explore clinical trials for potential treatment options. Resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Although no patient organizations are currently identified, participating in clinical trials may connect you with others facing similar challenges.
There are currently five active clinical trials investigating treatments for mucocutaneous leishmaniasis. Notably, miltefosine is an FDA-approved treatment, while other orphan drugs such as Imiquimod-Ferulic Acid and sodium stibogluconate are in development. For more information on ongoing trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=mucocutaneous%20leishmaniasis.
Actionable guidance for navigating care for mucocutaneous leishmaniasis
To navigate your care for mucocutaneous leishmaniasis, consider seeking out an infectious disease specialist with experience in tropical diseases. Additionally, you may want to explore clinical trials for potential treatment options. Resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Although no patient organizations are currently identified, participating in clinical trials may connect you with others facing similar challenges.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation for mucocutaneous leishmaniasis is limited due to its relatively low prevalence and the challenges associated with conducting systematic clinical studies. As a condition that affects fewer individuals, comprehensive data collection and characterization have not been prioritized. This can lead to feelings of uncertainty, but ongoing research aims to improve understanding and treatment options.
To navigate your care for mucocutaneous leishmaniasis, consider seeking out an infectious disease specialist with experience in tropical diseases. Additionally, you may want to explore clinical trials for potential treatment options. Resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Although no patient organizations are currently identified, participating in clinical trials may connect you with others facing similar challenges.
There are currently five active clinical trials investigating treatments for mucocutaneous leishmaniasis. Notably, miltefosine is an FDA-approved treatment, while other orphan drugs such as Imiquimod-Ferulic Acid and sodium stibogluconate are in development. For more information on ongoing trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=mucocutaneous%20leishmaniasis.
Actionable guidance for navigating care for mucocutaneous leishmaniasis
To navigate your care for mucocutaneous leishmaniasis, consider seeking out an infectious disease specialist with experience in tropical diseases. Additionally, you may want to explore clinical trials for potential treatment options. Resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Although no patient organizations are currently identified, participating in clinical trials may connect you with others facing similar challenges.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation for mucocutaneous leishmaniasis is limited due to its relatively low prevalence and the challenges associated with conducting systematic clinical studies. As a condition that affects fewer individuals, comprehensive data collection and characterization have not been prioritized. This can lead to feelings of uncertainty, but ongoing research aims to improve understanding and treatment options.
To navigate your care for mucocutaneous leishmaniasis, consider seeking out an infectious disease specialist with experience in tropical diseases. Additionally, you may want to explore clinical trials for potential treatment options. Resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Although no patient organizations are currently identified, participating in clinical trials may connect you with others facing similar challenges.
There are currently five active clinical trials investigating treatments for mucocutaneous leishmaniasis. Notably, miltefosine is an FDA-approved treatment, while other orphan drugs such as Imiquimod-Ferulic Acid and sodium stibogluconate are in development. For more information on ongoing trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=mucocutaneous%20leishmaniasis.
Actionable guidance for navigating care for mucocutaneous leishmaniasis
To navigate your care for mucocutaneous leishmaniasis, consider seeking out an infectious disease specialist with experience in tropical diseases. Additionally, you may want to explore clinical trials for potential treatment options. Resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Although no patient organizations are currently identified, participating in clinical trials may connect you with others facing similar challenges.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 2 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.